Untargeted lipidomics reveals specific lipid profiles in COVID-19 patients with different severity from Campania region (Italy)

Ciccarelli, Michele; Merciai, Fabrizio; Carrizzo, Albino; Sommella, Eduardo; Pietro, Paola Di; Caponigro, Vicky; Salviati, Emanuela; Musella, Simona; Sarno, Veronica Di; Rusciano, Mariarosaria; Toni, Anna Laura; Iesu, Paola; Izzo, Carmine; Schettino, Gabriella; Conti, Valeria; Venturini, Eleonora; Vitale, Carolina; Scarpati, Giuliana; Bonadies, D; Rispoli, Antonella; Polverino, Benedetto; Poto, S; Pagliano, Pasquale; Piazza, Ornella; Licastro, Danilo; Vecchione, Carmine; Campiglia, Pietro

doi:10.1016/j.jpba.2022.114827

Cited by 28 publications

(40 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This metabolic signature seems to be rather homogeneous worldwide, with equivalent results obtained when considering very distant geographical and cultural regions such as Mexico ( López-Hernández et al, 2021 ), Italy ( Saccon et al, 2021 ; Ghini et al, 2022b ; Ciccarelli et al, 2022 ), and Africa ( Li X. et al, 2022 ). Instead, characteristic but distinct metabotypes can be associated to pregnant women ( Id et al, 2022 ), newborn ( Kontou et al, 2021 ) and infantile ( Wang et al, 2021 ) COVID-19 population.…”

Section: Metabolic Signature Of the Acute Phase Of Sars-cov-2 Infectionmentioning

confidence: 55%

Metabolomics as a powerful tool for diagnostic, pronostic and drug intervention analysis in COVID-19

Bruzzone

Conde

Embade

et al. 2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

COVID-19 currently represents one of the major health challenges worldwide. Albeit its infectious character, with onset affectation mainly at the respiratory track, it is clear that the pathophysiology of COVID-19 has a systemic character, ultimately affecting many organs. This feature enables the possibility of investigating SARS-CoV-2 infection using multi-omic techniques, including metabolomic studies by chromatography coupled to mass spectrometry or by nuclear magnetic resonance (NMR) spectroscopy. Here we review the extensive literature on metabolomics in COVID-19, that unraveled many aspects of the disease including: a characteristic metabotipic signature associated to COVID-19, discrimination of patients according to severity, effect of drugs and vaccination treatments and the characterization of the natural history of the metabolic evolution associated to the disease, from the infection onset to full recovery or long-term and long sequelae of COVID.

show abstract

Section: Metabolic Signature Of the Acute Phase Of Sars-cov-2 Infectionmentioning

confidence: 55%

Metabolomics as a powerful tool for diagnostic, pronostic and drug intervention analysis in COVID-19

Bruzzone

Conde

Embade

et al. 2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…Bibliometric analyses of clinical lipidomics publications in 2022 according to separation techniques, detectors, and RPLC columns used. 51,60,61,68,77,[155][156][157]166,[212][213][214][215][310][311][312][313][314][322][323][324][325][326][327][328][329][330][331][332][333][334][335] All legends are in order of largest to smallest percentage. *Note: All techniques that represent ≥1.0% of total publications have been reported.…”

Section: Separation Sciencesmentioning

confidence: 99%

Chewing the fat: How lipidomics is changing our understanding of human health and disease in 2022

Géhin

Fowler

Trivedi

2023

Analytical Science Advances

View full text Add to dashboard Cite

Lipids are biological molecules that play vital roles in all living organisms. They perform many cellular functions, such as 1) forming cellular and subcellular membranes, 2) storing and using energy, and 3) serving as chemical messengers during intra‐ and inter‐cellular signal transduction. The large‐scale study of the pathways and networks of cellular lipids in biological systems is called “lipidomics” and is one of the fastest‐growing omics technologies of the last two decades. With state‐of‐the‐art mass spectrometry instrumentation and sophisticated data handling, clinical studies show how human lipid composition changes in health and disease, thereby making it a valuable medium to collect for clinical applications, such as disease diagnostics, therapeutic decision‐making, and drug development. This review gives a comprehensive overview of current workflows used in clinical research, from sample collection and preparation to data and clinical interpretations. This is followed by an appraisal of applications in 2022 and a perspective on the exciting future of clinical lipidomics.

show abstract

“…The study also provided further evidence for considering phospholipase A2 (PLA2) activity as a potential factor in the pathogenesis of COVID-19 and a possible therapeutic target. A similar study 83 focuses on patients from the Campania region, Italy. This knowledge has the potential to assist in developing or repurposing drugs which could be helpful at modulating the observed lipidome to minimize the effects of pro-inflammatory lipids and enhance the effect of anti-inflammatory or proresolving lipid mediators.…”

Section: Standardsmentioning

confidence: 99%

Section: Deuterated Drugs As Internal Ms Standardsmentioning

confidence: 99%

Deuterated Drugs and Biomarkers in the COVID-19 Pandemic

et al. 2022

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is a highly contagious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Initially identified in Wuhan (China) in December 2019, COVID-19 rapidly spread globally, resulting in the COVID-19 pandemic. Carriers of the SARS-CoV-2 can experience symptoms ranging from mild to severe (or no symptoms whatsoever). Although vaccination provides extra immunity toward SARS-CoV-2, there has been an urgent need to develop treatments for COVID-19 to alleviate symptoms for carriers of the disease. In seeking a potential treatment, deuterated compounds have played a critical role either as therapeutic agents or as internal MS standards for studying the pharmacological properties of new drugs by quantifying the parent compounds and metabolites. We have identified >70 examples of deuterium-labeled compounds associated with treatment of COVID-19. Of these, we found 9 repurposed drugs and >20 novel drugs studied for potential therapeutic roles along with a total of 38 compounds (drugs, biomarkers, and lipids) explored as internal mass spectrometry standards. This review details the synthetic pathways and modes of action of these compounds (if known), and a brief analysis of each study.

show abstract

Untargeted lipidomics reveals specific lipid profiles in COVID-19 patients with different severity from Campania region (Italy)

Cited by 28 publications

References 34 publications

Metabolomics as a powerful tool for diagnostic, pronostic and drug intervention analysis in COVID-19

Metabolomics as a powerful tool for diagnostic, pronostic and drug intervention analysis in COVID-19

Chewing the fat: How lipidomics is changing our understanding of human health and disease in 2022

Deuterated Drugs and Biomarkers in the COVID-19 Pandemic

Contact Info

Product

Resources

About